
Gustavo A. Rosario Benitez
Examiner (ID: 599, Phone: (571)270-7888 , Office: P/2838 )
| Most Active Art Unit | 2838 |
| Art Unit(s) | 2838 |
| Total Applications | 811 |
| Issued Applications | 625 |
| Pending Applications | 91 |
| Abandoned Applications | 129 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 10997454
[patent_doc_number] => 20160194401
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-07-07
[patent_title] => 'THERAPEUTIC AGENT FOR CHRONIC ARTHRITIDES DISEASES OF CHILDHOOD-RELATED DISEASES'
[patent_app_type] => utility
[patent_app_number] => 14/986884
[patent_app_country] => US
[patent_app_date] => 2016-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12238
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14986884
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/986884 | THERAPEUTIC AGENT FOR CHRONIC ARTHRITIDES DISEASES OF CHILDHOOD-RELATED DISEASES | Jan 3, 2016 | Abandoned |
Array
(
[id] => 15117705
[patent_doc_number] => 20190345485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-14
[patent_title] => CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 15/537418
[patent_app_country] => US
[patent_app_date] => 2015-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8662
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15537418
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/537418 | Chimeric antigen receptors and methods of use | Dec 17, 2015 | Issued |
Array
(
[id] => 11025125
[patent_doc_number] => 20160222080
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-08-04
[patent_title] => 'MULTIPLE TARGET T CELL RECEPTOR'
[patent_app_type] => utility
[patent_app_number] => 14/970974
[patent_app_country] => US
[patent_app_date] => 2015-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 7837
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14970974
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/970974 | MULTIPLE TARGET T CELL RECEPTOR | Dec 15, 2015 | Abandoned |
Array
(
[id] => 10822092
[patent_doc_number] => 20160168256
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-16
[patent_title] => 'MONOCLONAL ANTIBODY AND A METHOD THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/969461
[patent_app_country] => US
[patent_app_date] => 2015-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 35
[patent_no_of_words] => 15260
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14969461
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/969461 | Monoclonal antibody and a method thereof | Dec 14, 2015 | Issued |
Array
(
[id] => 17306311
[patent_doc_number] => 11207394
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-28
[patent_title] => Anti-mutated KRAS T cell receptors
[patent_app_type] => utility
[patent_app_number] => 15/528813
[patent_app_country] => US
[patent_app_date] => 2015-11-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26476
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 161
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15528813
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/528813 | Anti-mutated KRAS T cell receptors | Nov 23, 2015 | Issued |
Array
(
[id] => 10806549
[patent_doc_number] => 20160152707
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-02
[patent_title] => 'CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS'
[patent_app_type] => utility
[patent_app_number] => 14/947902
[patent_app_country] => US
[patent_app_date] => 2015-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 42
[patent_figures_cnt] => 42
[patent_no_of_words] => 43421
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14947902
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/947902 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS | Nov 19, 2015 | Abandoned |
Array
(
[id] => 12029574
[patent_doc_number] => 20170319674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-09
[patent_title] => 'USE OF ANTIBODIES FOR ENRICHMENT OF ENGINEERED T CELLS WITH EXOGENOUS IMMUNE RECEPTORS AND ANTIBODIES FOR USE IN DEPLETION OF ENGINEERED T CELLS'
[patent_app_type] => utility
[patent_app_number] => 15/528060
[patent_app_country] => US
[patent_app_date] => 2015-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 16241
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15528060
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/528060 | Use of antibodies for enrichment of engineered T cells with exogenous immune receptors and antibodies for use in depletion of engineered T cells | Nov 19, 2015 | Issued |
Array
(
[id] => 17133709
[patent_doc_number] => 11135245
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-05
[patent_title] => Engineered gd T-cells
[patent_app_type] => utility
[patent_app_number] => 14/944106
[patent_app_country] => US
[patent_app_date] => 2015-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 30415
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 196
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14944106
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/944106 | Engineered gd T-cells | Nov 16, 2015 | Issued |
Array
(
[id] => 10774751
[patent_doc_number] => 20160120907
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-05-05
[patent_title] => 'T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS'
[patent_app_type] => utility
[patent_app_number] => 14/934256
[patent_app_country] => US
[patent_app_date] => 2015-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 14749
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14934256
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/934256 | T cell receptor-deficient T cell compositions | Nov 5, 2015 | Issued |
Array
(
[id] => 18853908
[patent_doc_number] => 11851469
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-26
[patent_title] => Soluble heterodimeric T cell receptor, and preparation method and use thereof
[patent_app_type] => utility
[patent_app_number] => 15/524370
[patent_app_country] => US
[patent_app_date] => 2015-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 100
[patent_no_of_words] => 15208
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524370
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/524370 | Soluble heterodimeric T cell receptor, and preparation method and use thereof | Nov 3, 2015 | Issued |
Array
(
[id] => 11942128
[patent_doc_number] => 20170246279
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-31
[patent_title] => 'COMPOSITIONS AND METHODS FOR BOOSTING THE EFFICACY OF ADOPTIVE CELLULAR IMMUNOTHERAPY'
[patent_app_type] => utility
[patent_app_number] => 15/521794
[patent_app_country] => US
[patent_app_date] => 2015-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 17274
[patent_no_of_claims] => 75
[patent_no_of_ind_claims] => 47
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15521794
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/521794 | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy | Oct 26, 2015 | Issued |
Array
(
[id] => 10700560
[patent_doc_number] => 20160046708
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-02-18
[patent_title] => 'METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION'
[patent_app_type] => utility
[patent_app_number] => 14/923958
[patent_app_country] => US
[patent_app_date] => 2015-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 28715
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14923958
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/923958 | Methods to modulate lysine variant distribution | Oct 26, 2015 | Issued |
Array
(
[id] => 11040194
[patent_doc_number] => 20160237150
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-08-18
[patent_title] => 'MODULATED LYSINE VARIANT SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME'
[patent_app_type] => utility
[patent_app_number] => 14/923966
[patent_app_country] => US
[patent_app_date] => 2015-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 61
[patent_no_of_words] => 56868
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14923966
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/923966 | Modulated lysine variant species compositions and methods for producing and using the same | Oct 26, 2015 | Issued |
Array
(
[id] => 11612597
[patent_doc_number] => 09650445
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-05-16
[patent_title] => 'Immunotherapeutic molecules and uses'
[patent_app_type] => utility
[patent_app_number] => 14/918807
[patent_app_country] => US
[patent_app_date] => 2015-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 10
[patent_no_of_words] => 34971
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14918807
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/918807 | Immunotherapeutic molecules and uses | Oct 20, 2015 | Issued |
Array
(
[id] => 14174177
[patent_doc_number] => 10261093
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-16
[patent_title] => Isolating cells expressing secreted proteins
[patent_app_type] => utility
[patent_app_number] => 14/885460
[patent_app_country] => US
[patent_app_date] => 2015-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 59
[patent_no_of_words] => 15820
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14885460
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/885460 | Isolating cells expressing secreted proteins | Oct 15, 2015 | Issued |
Array
(
[id] => 10685858
[patent_doc_number] => 20160032003
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-02-04
[patent_title] => 'Therapeutic Use of Anti-CD22 Antibodies for Inducing Trogocytosis'
[patent_app_type] => utility
[patent_app_number] => 14/884313
[patent_app_country] => US
[patent_app_date] => 2015-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 34674
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14884313
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/884313 | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis | Oct 14, 2015 | Issued |
Array
(
[id] => 11992429
[patent_doc_number] => 20170296584
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-19
[patent_title] => 'METHODS FOR EXPANDING T CELL POPULATIONS'
[patent_app_type] => utility
[patent_app_number] => 15/517339
[patent_app_country] => US
[patent_app_date] => 2015-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 8757
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15517339
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/517339 | METHODS FOR EXPANDING T CELL POPULATIONS | Sep 23, 2015 | Abandoned |
Array
(
[id] => 10700762
[patent_doc_number] => 20160046909
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-02-18
[patent_title] => 'Use of Apoptotic Cells Ex Vivo to Generate Regulatory T Cells'
[patent_app_type] => utility
[patent_app_number] => 14/863274
[patent_app_country] => US
[patent_app_date] => 2015-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 9608
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14863274
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/863274 | Use of apoptotic cells ex vivo to generate regulatory T cells | Sep 22, 2015 | Issued |
Array
(
[id] => 10476152
[patent_doc_number] => 20150361169
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-12-17
[patent_title] => 'PURIFIED ANTIBODY COMPOSITION'
[patent_app_type] => utility
[patent_app_number] => 14/841474
[patent_app_country] => US
[patent_app_date] => 2015-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 64088
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841474
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/841474 | PURIFIED ANTIBODY COMPOSITION | Aug 30, 2015 | Abandoned |
Array
(
[id] => 10476151
[patent_doc_number] => 20150361168
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-12-17
[patent_title] => 'PURIFIED ANTIBODY COMPOSITION'
[patent_app_type] => utility
[patent_app_number] => 14/841439
[patent_app_country] => US
[patent_app_date] => 2015-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 64085
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841439
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/841439 | Purified antibody composition | Aug 30, 2015 | Issued |